Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer

Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 Yarden, 2001, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2, 127, 10.1038/35052073 Hudziak, 1987, Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells, Proc Natl Acad Sci USA, 84, 7159, 10.1073/pnas.84.20.7159 Faltus, 2004, Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells, Neoplasia, 6, 786, 10.1593/neo.04313 Choudhury, 2004, Her-2/neu as a paradigm of a tumor-specific target for therapy, Breast Dis, 20, 25, 10.3233/BD-2004-20104 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Montemurro, 2005, Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer, Clin Breast Cancer, 6, 77, 10.3816/CBC.2005.n.011 Montemurro, 2004, Trastuzumab-based combination therapy for breast cancer, Expert Opin Pharmacother, 5, 81, 10.1517/14656566.5.1.81 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Marty, 2005, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol, 23, 4265, 10.1200/JCO.2005.04.173 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 1659, 10.1056/NEJMoa052306 Slamon, 2005, Breast Cancer Res Treat, 94, S5 Press, 2002, Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens, J Clin Oncol, 20, 3095, 10.1200/JCO.2002.09.094 Fornier, 2002, HER2 testing and correlation with efficacy of trastuzumab therapy, Oncology (Williston Park), 16, 1340 Pauletti, 2000, Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry, J Clin Oncol, 18, 3651, 10.1200/JCO.2000.18.21.3651 Gancberg, 2002, Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing, Breast Cancer Res Treat, 74, 113, 10.1023/A:1016146130767 Mass, 2005, Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab, Clin Breast Cancer, 6, 240, 10.3816/CBC.2005.n.026 Jacobs, 1999, Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system, J Clin Oncol, 17, 1983, 10.1200/JCO.1999.17.7.1983 Cooley, 1999, Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu, Exp Hematol, 27, 1533, 10.1016/S0301-472X(99)00089-2 Lewis, 1993, Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies, Cancer Immunol Immunother, 37, 255, 10.1007/BF01518520 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, 6, 443, 10.1038/74704 Gennari, 2004, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2, Clin Cancer Res, 10, 5650, 10.1158/1078-0432.CCR-04-0225 Repka, 2003, Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study, Clin Cancer Res, 9, 2440 Christianson, 1998, NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer, Cancer Res, 58, 5123 Molina, 2001, Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells, Cancer Res, 61, 4744 Fornier, 2005, Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate, Ann Oncol, 16, 234, 10.1093/annonc/mdi059 Kostler, 2004, Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer, Clin Cancer Res, 10, 1618, 10.1158/1078-0432.CCR-0385-3 Sarup, 1991, Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth, Growth Regul, 1, 72 Valabrega, 2005, TGFalpha expression impairs trastuzumab-induced HER2 downregulation, Oncogene, 24, 3002, 10.1038/sj.onc.1208478 Austin, 2004, Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin, Mol Biol Cell, 15, 5268, 10.1091/mbc.e04-07-0591 Delord, 2005, Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma, Ann Oncol, 16, 1889, 10.1093/annonc/mdi405 Nagata, 2004, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients, Cancer Cell, 6, 117, 10.1016/j.ccr.2004.06.022 Yen, 2000, Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis, Oncogene, 19, 3460, 10.1038/sj.onc.1203685 Izumi, 2002, Tumour biology: herceptin acts as an anti-angiogenic cocktail, Nature, 416, 279, 10.1038/416279b Klos, 2003, Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone, Cancer, 98, 1377, 10.1002/cncr.11656 Lane, 2001, Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling, Ann Oncol, 12, S21, 10.1093/annonc/12.suppl_1.S21 Lu, 2001, Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin), J Natl Cancer Inst, 93, 1852, 10.1093/jnci/93.24.1852 Nahta, 2005, Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells, Cancer Res, 65, 11118, 10.1158/0008-5472.CAN-04-3841 Diermeier, 2005, Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation, Exp Cell Res, 304, 604, 10.1016/j.yexcr.2004.12.008 Nagy, 2005, Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line, Cancer Res, 65, 473, 10.1158/0008-5472.473.65.2 Bussolati, 2005, A modified trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer, Br J Cancer, 92, 1261, 10.1038/sj.bjc.6602507 Spector, 2005, Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies, J Clin Oncol, 23, 2502, 10.1200/JCO.2005.12.157 Xia, 2005, Combining lapatinib (GW57 2016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells, Oncogene, 24, 6213, 10.1038/sj.onc.1208774 Gomez, 2005, A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer, Proc Am Soc Clin Oncol, 23, 203s Blackwell, 2005, Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer, Proc Am Soc Clin Oncol, 23, 193s Spector, 2006, EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response, Proc Am Soc Clin Oncol, 24 GeyerCameronLindquistA phase III randomized, open label, international study comparing lapatinib and capecitabine vs capecitabine in women with refractory or advanced metastatic breast cancer (EGF 100151). ASCO Scientific Special Session: Lapatinib in Trastuzumab Resistant Breast Cancerhttp://www.asco.org (31 August 2006, date last accessed). Lin, 2006, Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer, Proc Am Soc Clin Oncol, 24 Storniolo, 2005, A phase I, open-label study of lapatinib (GW57 2016) plus trastuzumab; a clinically active regimen, Proc Am Soc Clin Oncol, 23, 559, 10.1200/jco.2005.23.16_suppl.559 Normanno, 2002, Cooperative inhibitory effect of ZD 1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth, Ann Oncol, 13, 65, 10.1093/annonc/mdf020 Warburton, 2004, Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD 1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction, Clin Cancer Res, 10, 2512, 10.1158/1078-0432.CCR-03-0244 Arteaga, 2004, ECOG1100: a phase I–II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib ([Isquo]Iressa) in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca), Breast Cancer Res Treat, 88, S15 Normanno, 2005, Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?, Ann Oncol, 16, 1709, 10.1093/annonc/mdi325 Agus, 2002, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth, Cancer Cell, 2, 127, 10.1016/S1535-6108(02)00097-1 Cho, 2003, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, 421, 756, 10.1038/nature01392 Nahta, 2004, The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells, Cancer Res, 64, 2343, 10.1158/0008-5472.CAN-03-3856 Chan, 2002, First report: a phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy, Proc Am Soc Clin Oncol, 21, 44a Pegram, 2004, Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF), Breast Cancer Res Treat, 88, S124 Batra, 1992, Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin, Proc Natl Acad Sci USA, 89, 5867, 10.1073/pnas.89.13.5867 Rosenblum, 2000, A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor, Int J Cancer, 88, 267, 10.1002/1097-0215(20001015)88:2<267::AID-IJC19>3.0.CO;2-G Nahta, 2006, Herceptin: mechanisms of action and resistance, Cancer Lett, 232, 123, 10.1016/j.canlet.2005.01.041 Tan-Chiu, 2005, registHER: a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer, Proc Am Soc Clin Oncol, 23, 46s Gelmon, 2004, Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories, Clin Breast Cancer, 5, 52, 10.3816/CBC.2004.n.010 Fountzilas, 2003, Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group, Clin Breast Cancer, 4, 120, 10.3816/CBC.2003.n.017 Tripathy, 2004, Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression, J Clin Oncol, 22, 1063, 10.1200/JCO.2004.06.557 Montemurro, 2006, Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy, Oncologist, 11, 318, 10.1634/theoncologist.11-4-318 Montemurro, 2005, Continuation of trastuzumab beyond disease progression, J Clin Oncol, 23, 2866, 10.1200/JCO.2005.05.177